Items where authors include "Nathan, P."

Export as [feed] Atom [feed] RSS
Jump to: Article
Number of items: 9.

Article

Sacco, J.J., Jackson, R., Corrie, P. et al. (18 more authors) (2024) A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 202. 114009. ISSN 0959-8049

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G., Brown, S. et al. (24 more authors) (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. ISSN 0732-183X

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G. orcid.org/0000-0002-9952-8440, Brown, S. orcid.org/0000-0002-7975-7537 et al. (24 more authors) (2023) Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). Journal of Clinical Oncology. JCO2300236. ISSN 0732-183X

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Eisen, T., Frangou, E., Oza, B. et al. (22 more authors) (2020) Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 38 (34). pp. 4064-4075. ISSN 0732-183X

Bullement, A. orcid.org/0000-0001-7091-0972, Nathan, P., Willis, A. et al. (6 more authors) (2019) Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma. PharmacoEconomics - Open, 3 (3). pp. 377-390. ISSN 2509-4262

Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Ahmad, S.S., Qian, W., Ellis, S. et al. (26 more authors) (2015) Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25 (5). pp. 432-442. ISSN 0960-8931

Ricketts, C.J., Morris, M.R., Gentle, D. et al. (7 more authors) (2013) Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics, 5. 16. ISSN 1868-7075

This list was generated on Sun Apr 14 09:26:42 2024 BST.